Table 3.

Cytogenetic abnormalities of MDS patients stratified by age groups

	Total (n = 93)	Younger MDS patients (n = 50)	Older MDS patients (n = 43)	p value
Genes mutation total events (mean)	1.78	1.64	1.95	0.216
TET2	72 (77.4%)	41 (82.0%)	31 (72.1%)	0.255
ASXL1	21 (22.6%)	10 (20.0%)	11 (25.6%)	0.521
U2AF1	18 (19.4%)	10 (20.0%)	9 (20.9%)	0.912
RUNX1	9 (9.7%)	3 (6.0%)	6 (14.0%)	0.196
NRAS	7 (7.5%)	2 (4.0%)	5 (11.6%)	0.164
TP53	5 (5.4%)	2 (4.0%)	3 (7.0%)	0.526
SF3B1	5 (5.4%)	2 (4.0%)	3 (7.0%)	0.526
DNMT3A	5 (5.4%)	2 (4.0%)	3 (7.0%)	0.526
CEBPA	5 (5.4%)	3 (6.0%)	2 (4.7%)	0.774
SRSF2	5 (5.4%)	0 (0%)	5 (11.6%)	N/A
ETV6	4 (4.3%)	3 (6%)	1 (2%)	0.384
SETBP1	3 (3.2%)	2 (4%)	1 (2%)	0.649
JAK2	2 (2.3%)	0 (0%)	2 (5%)	N/A
PHF6	1 (1.1%)	0 (0%)	1 (2%)	N/A
NPM1	1 (1.1%)	0 (0%)	1 (2%)	N/A
IDH2	1 (1.1%)	0 (0%)	1 (2%)	N/A
EZH2	1 (1.1%)	1 (2%)	0 (0%)	N/A
CBL	1 (1.1%)	1 (2%)	0 (0%)	N/A
DNA methylation (frequency, %)	72 (77.4%)	41 (82%)	31 (72.1%)	0.547
RNA spliceosome (frequency, %)	28 (30.1%)	12 (24%)	16 (37.2%)	0.166
Chromatin remodelling (frequency, %)	22 (23.7%)	11 (22%)	11 (25.6%)	0.685
Transcriptional deregulation (frequency, %)	14 (15.1%)	6 (12%)	8 (18.6%)	0.375
Activated signalling (frequency, %)	10 (10.8%)	3 (6%)	7 (16.3%)	0.111